-
Product Insights
Net Present Value Model: RHB-204
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RHB-204 Drug Details RHB-204 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RHB-204
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RHB-204 Drug Details RHB-204 is under development for the treatment of pulmonary non-tuberculous mycobacteria...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ondansetron hydrochloride CR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ondansetron hydrochloride CR Drug Details Ondansetron hydrochloride (RHB-102, Bekinda) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (clarithromycin + clofazimine + rifabutin)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (clarithromycin + clofazimine + rifabutin) Drug Details RHB-104, a fixed dose combination of rifabutin,...
-
Company Insights
Malaysia Retail Banking Competitor Benchmarking – Analyzing Top Players Market Performance and Share, Retention Risk, Financial Performance, Customer Relationships, Customer Satisfaction and Actionable Steps
All Malaysian banks covered in this report increased their total divisional assets (TDA) from 2020 to 2021. This indicates that they have managed to cope with the impact of the COVID-19 pandemic. Public Bank and Maybank increased their share of the Malaysian retail banking market in multiple segments from 2011 to 2021, entrenching their positions. The Malaysia retail banking competitor benchmarking report analyzes financial performance, depth of customer relationships, and customer satisfaction. It ranks Malaysia’s top banks across a range...
-
Product Insights
Gastritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of...
-
Product Insights
Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis – Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape. Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis – Drugs In...
-
Sector Analysis
Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
The NTM market size in the US, the UK, and Japan was $8.59 billion in 2021 and is expected to achieve a CAGR of more than 2% during 2021-2031. The NTM market will grow as the diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections are expected to increase in the US, the UK, and Japan between 2021 and 2031. The NTM market research report provides an analysis of the key dynamics of the NTM drugs market. The report also offers...
-
Sector Analysis
PharmaPoint: Crohn’s Disease – Global Drug Forecast and Market Analysis to 2026
Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized...
-
Sector Analysis
Consumer Payments Country Snapshot: Malaysia 2016
"Consumer Payments Country Snapshot: Malaysia 2016", report examines the consumer payments market in Malaysia, considering payment cards, online payments, P2P payments, and newer payment technologies such as mobile wallets and contactless. This report also examines the main regulatory players in the Malaysian market. In spite of cash use remaining relatively high in Malaysia, new payment technologies are expected to gain momentum in the short term. The key opportunity is to provide products and services that are as easy to use,...